BNTX:NASDAQ
BioNTech SE - ADR
$99.26
arrow_upward
+0.81%(+0.80) 1D
$99.26
0.00% (0.00)
bedtimeAfter hours
Closed: Sep 24, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$97.62
High
$99.93
Low
$97.05
Mkt. cap
24.93B
Avg. vol.
1.45M
Volume
0.00
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.64
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
Open
$97.62
High
$99.93
Low
$97.05
Mkt. cap
24.93B
Avg. vol.
1.45M
Volume
0.00
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.64
Beta
1.27
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
AD HOC NEWS
·
1 hour ago
BioNTech SE stock rises 0.8 percent ahead of the open
Insider Monkey
·
9 hours ago
Could a New Vaccine Formula XFG Give Pfizer (PFE) and BioNTech (BNTX) a Post-Pandemic Revenue Boost?
Stock Titan
·
9 hours ago
BioNTech (BNTX) CEO Ugur Sahin sold shares on two days under a trading plan set in June.
AD HOC NEWS
·
18 hours ago
CureVac stock was delisted after its BioNTech merger
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR